Article Details
Retrieved on: 2022-09-22 01:54:12
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Under the terms of the agreement, Pfizer will make a $20M equity investment, have options to license CytoReason's platform and disease models, and ...
Article found on: www.marketscreener.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here